复星医药(02196.HK)：子公司”HLX14“药品注册申请获药监局受理

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., has had its drug registration application for HLX14, a biosimilar to Prolia®, accepted by the National Medical Products Administration of China [1] Group 1 - HLX14 is a recombinant anti-RANKL fully human monoclonal antibody injection [1] - The application is classified as a therapeutic biological product under category 3.3 [1] - The indications for HLX14 are based on all approved indications of Prolia® in China [1]